These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23348532)

  • 1. The utility of NT-proBNP and various echocardiographic methods in the determination of doxorubicin induced subclinical late cardiotoxicity.
    Yildirim A; Tunaoglu FS; Kambur K; Pinarli FG
    Kardiol Pol; 2013; 71(1):40-6. PubMed ID: 23348532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
    Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
    Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy.
    Soker M; Kervancioglu M
    Saudi Med J; 2005 Aug; 26(8):1197-202. PubMed ID: 16127512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.
    Kremastinos DT; Hamodraka E; Parissis J; Tsiapras D; Dima K; Maisel A
    Am Heart J; 2010 Jan; 159(1):68-74. PubMed ID: 20102869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
    Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
    Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.
    Pongprot Y; Sittiwangkul R; Charoenkwan P; Silvilairat S
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):589-95. PubMed ID: 23018571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of plasmatic levels of B-natriuretic peptide with echocardiographic indicators of left ventricle function after doxorubicin therapy].
    Elbl L; Vásová I; Navrátil M; Vorlícek J; Malásková L; Spinar J
    Vnitr Lek; 2006 Jun; 52(6):563-70. PubMed ID: 16871759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
    Germanakis I; Kalmanti M; Parthenakis F; Nikitovic D; Stiakaki E; Patrianakos A; Vardas PE
    Int J Cardiol; 2006 Apr; 108(2):212-5. PubMed ID: 16290101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
    Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
    Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Echocardiographic evaluation of systolic and diastolic function: a preoperative study of correlation with serum NT-proBNP.
    Frederiksen CA; Juhl-Olsen P; Jakobsen CJ; Sloth E
    J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):197-203. PubMed ID: 21955828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy.
    Arteaga E; Araujo AQ; Buck P; Ianni BM; Rabello R; Mady C
    Am Heart J; 2005 Dec; 150(6):1228-32. PubMed ID: 16338263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
    Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
    Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cardiac effects of treatment for childhood leukemia.
    Urbanova D; Urban L; Simkova I; Danova K; Mikuskova E; Mladosievicova B
    Neoplasma; 2010; 57(2):179-83. PubMed ID: 20099983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation to NT-ProBNP and remodeling after cardiac surgery.
    Boer BP; Vieira ML; Sampaio RO; Abensur H; Oliveira AG; Fernandes JR; Grinberg M
    Arq Bras Cardiol; 2013 May; 100(5):469-75. PubMed ID: 23579620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue Doppler velocities of mitral annulus and NT-proBNP in patients with heart failure.
    Tretjak M; Verovnik F; Benko D; Kozelj M
    Eur J Heart Fail; 2005 Jun; 7(4):520-4. PubMed ID: 15921789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients.
    Hongkan W; Soongswang J; Veerakul G; Sanpakit K; Punlee K; Rochanasiri W; Udompunturak S
    J Med Assoc Thai; 2009 Nov; 92(11):1450-7. PubMed ID: 19938736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.